Cyteir Therapeutics, Inc.·4

Feb 16, 4:00 PM ET

George Jean 4

4 · Cyteir Therapeutics, Inc. · Filed Feb 16, 2024

Insider Transaction Report

Form 4
Period: 2024-02-14
George Jean
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-14$1.69/sh+14,150$23,91414,150 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-02-1414,1500 total
    Exercise: $1.69From: 2024-02-03Exp: 2033-02-03Common Stock (14,150 underlying)
Holdings
  • Common Stock

    (indirect: See Footnote)
    2,444,265
Footnotes (1)
  • [F1]Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION